1Obici L,Perfetti V,Palladini G,et al.Clinical aspects of systemic amyloid diseases.Biochimica et Biophysica Acta,2005,1753:11-22.
2Lachmann HJ,Booth DR,Booth SE,et al.Misdiagnosis of hereditary amyloidosis as AL(primary)amyloidosis.N Engl J Med,2002,346:1786-1791.
3Yang M,Yordanov B,Lery Y,et al.The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.Biochemistry,2006,45(39):11992-12002.
4Sekijima Y,Dendle MT,Wiseman RL,et al.R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization,but not by the kinetic mechanism characterizing T119 interallelic trans-sup-pression.Amyloid,2006,13(2):57-66.
5Merlini G,Bellotti V.Molecular mechanisms of amyloidosis,N Engl J Med,2003,349:583-596.
6Booth DR,Sunde M,Bellotti V,et al,Instability,unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis,Nature,1997,385:787-793.
8Rapezzi C,Perugini E,Salvi F.Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis:Towards tailoring of therapeutic strategies?Amyloid,2006,13(3):143-153.
9Hawkins PN.Hereditary systemic amyloidosis with renal involvement.J Nephrol,2003,16:443-448.
10Ihse E, Suhr OB, Hellman U, et al. Variation in amount of wild- type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med, 2011, 89: 171-180.
